HomeCompareNGENF vs NNN

NGENF vs NNN: Dividend Comparison 2026

NGENF yields 50.63% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NGENF wins by $381.6K in total portfolio value
10 years
NGENF
NGENF
● Live price
50.63%
Share price
$3.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$407.1K
Annual income
$83,327.27
Full NGENF calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — NGENF vs NNN

📍 NGENF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNGENFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NGENF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NGENF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NGENF
Annual income on $10K today (after 15% tax)
$4,303.80/yr
After 10yr DRIP, annual income (after tax)
$70,828.18/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, NGENF beats the other by $68,598.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NGENF + NNN for your $10,000?

NGENF: 50%NNN: 50%
100% NNN50/50100% NGENF
Portfolio after 10yr
$216.3K
Annual income
$42,974.97/yr
Blended yield
19.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

NGENF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-3.3
Piotroski
1/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NGENF buys
0
NNN buys
2
PoliticianChamberTickerTypeAmountDate
Lisa McClain🏢 House$NNN▼ Sell$1,001 - $15,0002025-08-13
Lisa McClain🏢 House$NNN▲ Buy$1,001 - $15,0002025-06-17
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002023-05-25
Ro Khanna🏢 House$NNN▼ Sell$1,001 - $15,0002022-01-20
Zoe Lofgren🏢 House$NNN▲ Buy$1,001 - $15,0002021-09-30
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002020-03-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNGENFNNN
Forward yield50.63%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$407.1K$25.5K
Annual income after 10y$83,327.27$2,622.67
Total dividends collected$325.7K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: NGENF vs NNN ($10,000, DRIP)

YearNGENF PortfolioNGENF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$15,763$5,063.29$10,735$614.96+$5.0KNGENF
2$24,326$7,459.26$11,572$708.43+$12.8KNGENF
3$36,787$10,758.11$12,531$819.53+$24.3KNGENF
4$54,567$15,204.60$13,633$952.29+$40.9KNGENF
5$79,464$21,077.77$14,909$1,111.84+$64.6KNGENF
6$113,713$28,686.96$16,392$1,304.77+$97.3KNGENF
7$160,039$38,365.61$18,129$1,539.52+$141.9KNGENF
8$221,705$50,462.91$20,173$1,827.08+$201.5KNGENF
9$302,558$65,333.74$22,597$2,181.81+$280.0KNGENF
10$407,064$83,327.27$25,491$2,622.67+$381.6KNGENF

NGENF vs NNN: Complete Analysis 2026

NGENFStock

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.

Full NGENF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this NGENF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NGENF vs SCHDNGENF vs JEPINGENF vs ONGENF vs KONGENF vs MAINNGENF vs ADCNGENF vs EPRTNGENF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.